Aptose Biosciences News and Activities

Aptose Biosciences is owned by Hanmi.

Hanmi is a company listed under the stock ticker HANPF (KR).

Hanmi has a direct presence in 2 countries.

They are in:

• Pharmaceuticals50%
• Biotechnology50%

Acquisition, funding and merger involving Hanmi.

• Hanmi has acquired Aptose Biosciences (posted on July 1 2026).

View the org chart displaying its 11 main executives

Most searched biographies at Aptose Biosciences

• William Rice, Chairman, President and Chief Executive Officer
• Mark Vincent, Director
• Erich Platzer, Director

Popular executive movements at Hanmi

• Hwang Sang Yeon has joined the company as Chief Executive Officer  (posted on April 1 2026).
• Park Jaehyun, Chief Executive Officer, has left the company  (posted on April 1 2026).

Create your alert
to follow the executive moves at Aptose Biosciences.

Hanmi has 2,428 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

• Eli Lilly has announced the acquisition of AtaiBeckley  (posted on July 17 2026).
• GSK has acquired Nuvalent (posted on July 17 2026).
• Clearside Biomedical has gone out of its bankruptcy protection  (posted on July 15 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Robert Gould - Board Member at Fulcrum Therapeutics

Learn more about the Biotechnology industry

Press releases by Aptose Biosciences

• Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering
• Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering
• Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy
• Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials
• Aptose Reports Results for the Third Quarter 2024
• Aptose Announces Results from Special Meeting of Shareholders
• Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib
• Aptose Announces Adjournment of its Special Meeting of Shareholders
• Press Releases
• Aptose Announces Receipt of Deficiency Notice from Nasdaq
• View more press releases Close

Social media about Aptose Biosciences

• Aptose Biosciences on Wikipedia, Google News & Yahoo Finance
• Aptose Biosciences on LinkedIn, X (Twitter) & YouTube